Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms

GSK reports breakthrough results in chronic hepatitis B trials

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data

Subcutaneous Saphnelo cuts lupus disease activity in phase III trial

SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage

Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India

It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65

ProBioGen, Zag Bio seal manufacturing deal to fast-track type 1 diabetes therapy into clinic

The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation

FDA grants priority review to Tzield for youngest Type 1 diabetes patients

Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D